Bioage Labs Inc (BIOA)
BioAge Labs Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. The company uses a technology platform and human datasets designed to identify drug targets from biological changes associated with aging. Its lead candidate, BGE-102, is an orally available, brain-penetrant small-molecule NLRP3 inhibitor in Phase 1 clinical development for atherosclerotic cardiovascular disease, with additional evaluation for diabetic macular edema and geographic atrophy. BioAge Labs is also advancing APJ agonist programs for obesity, including both oral and parenteral approaches. In addition, the company has a collaboration with Novartis Pharma AG to study and validate novel therapeutic targets related to aging and age-associated diseases. BioAge Labs was incorporated in 2015 and is based in Emeryville, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BIOA
|
$15.24
|
-32.3% Downside
|
Overvalued
|
$49.50
|
120.0% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-11.1x
|
2.6x
|
96.8x
|
992.2 M
|
618 M
|
0.4%
|
78.6%
|
31.2
|
—
|
98.6%
|
